Veru Inc Dossier
Financial Snapshot
Revenue, profitability, returns, debt, and capital allocation
Revenue $0TTM through 30 Jun 2026
Net Income -$13.6MTTM through 30 Jun 2026
Free Cash Flow -$26MTTM through 30 Jun 2026
Margins
| Current |
|---|
Returns
-51.7%ROE
-36.8%ROA
Balance Sheet Health
Debt / Equity0.10x
Current Ratio6.19x
Net Debt-$27.6Mnet cash position
Cash & Equivalents$23.9M
Quality Metrics
Altman Z-Score-10.64
Piotroski F-Score1 / 9
Earnings-Beat Rate75.0%
Multi-Year Trend
RevenueFY2024: $16.9M
Diluted EPSFY2025: $-1.55
Dividend
No dividend
Capital Allocation
R&D Spend$11.8M
Segment Performance
| Segment | Revenue | YoY | Outlook |
|---|---|---|---|
| Cardiometabolic and Inflammatory Diseases | $0 | View detailsInterim analysis results expected in Q1 calendar year 2027. |
Filing Detail Members
This section is available to registered members. Create a free account or sign in to unlock the full breakdown.